• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma Pulse 3/28/24: The Fight for AI Talent, Atopic Dermatitis and Mental Health & more


The latest news for pharma industry insiders.

How Often are Retracted microRNA Biomarker Articles Cited in Future Research?

Systematic review of over 800 retracted articles suggest that better identification of postretraction citations should be implemented.

Atopic Dermatitis and Mental Health

Adults and children with atopic dermatitis experience worse anxiety and depression as disease becomes more severe.

The Fight for AI Talent: Pay Million-Dollar Packages and Buy Whole Teams

Search for AI expertise heats up amid a shortage of candidates and as layoffs hit other areas of tech

Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson’s Disease

Indivi has entered into an agreement with Biogen to advance digital health technology and develop digital biomarkers for Parkinson’s disease. As part of the agreement, Biogen will license KonectomTM to Indivi, a smartphone-based digital biomarker platform that assesses neurological functions remotely for more precise, frequent measurement of disease evolution.

Advanced Chemistry Development, Inc., (ACD/Labs) on LinkedIn:

AI and Machine Learning rely on data, but not all data is created alike.
ACD/Labs’ Andrew Anderson discusses how AI can bring data into more usable formats, the role it plays in drug development, and more with Pharmaceutical Executive.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs